Early PARacetamol (EPAR) trial: a study protocol for a randomised controlled trial of early paracetamol to promote closure of the ductus arteriosus in preterm infants

INTRODUCTION: The optimal management of patent ductus arteriosus (PDA) remains contentious. The medications used to treat PDA are often non-steroidal anti-inflammatory drugs, which are associated with a number of unwanted adverse effects. Paracetamol is a medication with an excellent safety profile...

Descripción completa

Detalles Bibliográficos
Autores principales: Schindler, Tim, Smyth, John, Bolisetty, Srinivas, Michalowski, Joanna, Lui, Kei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Paediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830666/
https://www.ncbi.nlm.nih.gov/pubmed/31666270
http://dx.doi.org/10.1136/bmjopen-2019-031428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830666/
https://www.ncbi.nlm.nih.gov/pubmed/31666270
http://dx.doi.org/10.1136/bmjopen-2019-031428

Ejemplares similares